RECOMMEND Platform Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT06526533

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose supportive care
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06526533
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06526533. Randomized; no masking; primary purpose supportive care. Start 2026-03-23 (actual); primary completion 2028-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RECOMMEND Platform Trial
Acronym
RECOMMEND
Condition
Extracorporeal Membrane Oxygenation Complication
Condition
ARDS (Acute Respiratory Distress Syndrome)
Condition
Intensive Care Medicine
Condition
Cardiac Arrest (CA)
Condition
Critical Illness
Intervention (Other)
Liberal RBC Transfusion
Intervention (Other)
Restrictive RBC Transfusion
Lead sponsor
Australian and New Zealand Intensive Care Research Centre (class: other)
Collaborator
Monash University (class: other)
Collaborator
Berry Consultants (class: other)
Collaborator
Research Path (class: not stated)

Record details

Record id
cardio:ct-nct06526533
Content hash
17dfd96b4e68e414c7dac2e57044b1482fcfef937180e048328af3b9b5e20268